Dayton violence interruption plan eyes hotspots: Miami Chapel, North Riverdale
Cure Violence Global recently completed an assessment that says Dayton is good fit for its violence prevention and reduction model that treats violence like a contagious disease. The organization identified potential target areas of North Riverdale in north Dayton and Miami Chapel in west Dayton.
A Dayton Police Department analysis of firearm-related homicides and felonious assaults from 1999 to 2024 found that violence has been concentrated in areas including the DeSoto Bass Courts in Miami Chapel and the North Main Street corridor, by the Santa Clara and North Riverdale neighborhoods.
Studies indicate that Cure Violence Global programs in other U.S. cities have led to large reductions in violence, shootings and killings, said Mayor Jeffrey Mims Jr., who believes Dayton's new program will launch in mid- to late summer.
"It's a problem we want to prevent," he said. "I don't want to lose one more life."
Cure Violence Global is a Chicago-based organization that helps communities create violence prevention and reduction programs that take a public health approach to combating bloodshed.
The group worked closely with the city to complete a "readiness assessment" to determine if its model could work in the Gem City. CVG says Dayton has the capacity and the "political will" to launch a successful program.
CVG recommends that Public Health — Dayton & Montgomery County should be the oversight agency for the program, and the group said it can and will help find a community-based organization to implement the model.
Jennifer Wentzel, health commissioner with Public Health — Dayton & Montgomery County, said the agency "has been asked to play a role in addressing violence as a public health issue, and we are working to determine the most effective way for Public Health to support a meaningful, evidence-based and community-centered solution."
CVG's readiness assessment says Miami Chapel and North Riverdale are potential target areas. Miami Chapel starts at U.S. 35 near James H. McGee Blvd. and runs south past Germantown Pike and DeSoto Bass, to Louise Troy Elementary and the Humane Society. North Riverdale is a long neighborhood of homes between Main Street and Riverside Drive, running north from Ridge Avenue just past Siebenthaler.
A Dayton Daily News investigation earlier this year found that North Riverdale and Residence Park (in west Dayton) had the most incidents of violent gun crime in the city last year, and Miami Chapel had more gun violence than most city neighborhoods.
Maps created by the Dayton Police Department of firearm-related homicides and felonious assaults in the last five and the last 26 years suggest that hotspots included parts of Miami Chapel, the Summit Square apartment complex and sections of the North Main Street corridor, close to and around North Riverdale.
The readiness assessment says that information provided by the Dayton Police Department suggests that the nature of violent incidents in the city is consistent with other places where the CVG model has been implemented.
"Shootings and homicides take place in mostly public spaces in the community between individuals and groups who are in conflict for various reasons ranging from the sale of substances to interpersonal conflicts (often fueled by social media) to other 'on the spot' transactional disputes," the report states.
CVG recommends that Dayton's program employ 7-10 team members for every target area, which includes violence interrupters, outreach workers and supervisors and program managers. The assessment says a program in a target area could cost about $565,000 annually.
CVG's model calls for hiring and training violence interrupters who try to prevent violence by identifying and mediating conflicts in the community before they can escalate. These "credible messengers" will try to link vulnerable community members who are at a high risk of being involved in violence with services like housing, food, employment and educational assistance and job skills training.
CVG says its model helped reduce killings by 75% in Charlotte; 43% in St. Louis; 32% in Baltimore; and 18% in Milwaukee. The organization says violence interruption programs in New York, Philadelphia and New Orleans resulted in sizable declines in shootings.
Mayor Mims said Dayton overall is a safe place, and the Gem City is safer than some other U.S. urban areas. But he said there is still too much violence in the community, and this program hopefully will help change that.
"It makes all the sense in the world for us to do this," he said. "Getting this right means so, so much to every citizen, born and unborn, and every citizen who passes through Dayton, plus those who live here."
Mims said more community members, and young people especially, need to be taught conflict resolution skills. Mims also said the violence interruption program is one part of his peace campaign, and the other components will focus on youth development and community engagement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
7 hours ago
- CBS News
State Department pauses visitor visas for Gaza residents in need of medical care in U.S.
For nearly two years, humanitarian groups have been working to bring children from Gaza to Chicago and other U.S. cities for lifesaving medical care. Those groups said they were devastated by the State Department's sudden decision to halt visitor visas from Gaza over the weekend—putting the work of groups that have brought those sick or injured kids here in jeopardy. The State Department said the pause is temporary, but it was initiated to investigate claims that there are recipients who have ties to terrorist groups. One-year-old Saedra was born with congenital defects in both legs. After losing her home in Gaza, she and her mother were evacuated by the humanitarian nonprofit Heal Palestine to get care here in Chicago. It was a similar journey for Jood Damo, who was 2 years old when CBS News Chicago interviewed him last year. He was brought to Chicago to receive treatment for a serious leg injury he sustained in an Israeli bombing that killed his mother in 2023. Saedra and Damo were brought to Chicago through temporary visas. Now, that program is on pause after the weekend's announcement. During an interview on Face the Nation, Secretary of State Marco Rubio defended the decision. "There is evidence, it's been presented to us by numerous congressional offices, that some of the organizations bragging about and involved in acquiring these visas have strong links to terrorist groups like Hamas," he said. Rubio did not elaborate on what kind of evidence they are looking into or how long this pause will be in effect. Meanwhile, Heal Palestine, which has evacuated at least 63 injured children and 148 total people from Gaza, released a statement, saying they're distressed and emphasized, "This is a medical treatment program, not a refugee resettlement program." "So, once we've identified a hospital or a group of physicians who can provide that care, we can apply for a medical visa for those children," volunteer Talaha Baquar said. Baquar explained the process early this month when three severely wounded children from Gaza arrived at San Francisco International Airport. "So the children are here for medical care. They do not stay. So once their medical care has been completed, they will either go primarily to Egypt, where Heal Palestine facilitates housing for them until they wait to be reunited with their families," Baquar said. Rubio said only a small number of these visas were being issued to children. According to the United Nations, as of July, over 17,000 Palestinian children in Gaza were killed, and 33,000 were injured by the Israeli military since October 2023.
NBC News
8 hours ago
- NBC News
Time is running out for kids with a rare disease, parents say, unless the FDA acts
Gilbert Dryden probably only has enough medication to get him through the end of October, his mother, Madison, figures. Seven-month-old Gilbert has a rare genetic condition called Barth syndrome, one that can have dire consequences, like heart failure, extreme muscle weakness and a dramatically reduced life expectancy. Children who die early often don't see their fifth birthday. Two infant deaths were reported within the past week, according to the Barth Syndrome Foundation. What's been keeping Gilbert alive and functioning relatively well, according to his family, is an experimental drug called elamipretide, made by Stealth BioTherapeutics. Small studies have suggested it's safe and effective in treating the ultra-rare illness. Just 150 people in the U.S. have the condition. 'Our kids are dying. We have seen that this drug works,' said Kate McCurdy, a co-founder of the Barth Syndrome Foundation. 'This drug totally saves the lives of babies.' After a more than decade-long process to bring the drug to market, the treatment's approval has repeatedly hit roadblocks with the Food and Drug Administration. One setback occurred in the spring, when an FDA inspection found problems at a Stealth manufacturing facility. The problems weren't made public, but apparently weren't egregious enough to warrant regulatory action. The company said the issues have been resolved. In late May, after an advisory panel voted earlier (in October 2024) to recommend the therapy, the FDA declined to approve it. The agency didn't reveal why. An ultra-rare disease like Barth syndrome with an ultra-small population of patients who can be tested for clinical efficacy faces barriers for FDA drug approval. There aren't enough patients to do robust, randomized clinical trials, McCurdy said. 'It is virtually impossible to conduct trials that yield data that are conclusive beyond a reasonable doubt. Statistically, you just can't do that,' she said. Weeks later and following a meeting between Needham, Massachusetts-based Stealth and the FDA in late June, the real bombshell came: The company said the agency informed Stealth on Aug. 4 that it would need to resubmit a new drug application — for the third time. It could use a special pathway called 'accelerated approval' in that submission, but the manufacturing issue would extend the timeline to review elamipretide for at least another six months, according to the company. Stealth said that no additional clinical data or safety data was requested. But without any course correction in the process, the private company could run out of money. The delay is devastating to families like the Drydens. 'When we heard this news, we immediately went to the fridge to count how many vials we have left, because that's how long we have this medication. That's the only guarantee we have right now that Gilbert is not going to die,' said Madison Dryden, 35, of Aurora, Colorado. 'It's the highest level of desperation.' On Monday, Stealth announced that it did submit its third application for approval of elamipretide — asking for an accelerated pathway under a significantly tighter timeline than what the agency initially recommended. What is Barth syndrome? Madison Dryden and her husband, Andrew, weren't sure what was wrong with Gilbert in the hours and days after his Christmas Eve birth in 2024. 'His heart function was so low. He was so sick, his body and his feet were purple, his hands were purple,' Dryden said. 'He couldn't eat.' Gilbert was admitted to the neonatal intensive care unit and received lifesaving care as doctors urgently tried to figure out a diagnosis. Within a matter of days, Dryden said, Gilbert was airlifted to Children's Hospital Colorado with a heart that was struggling to adequately pump blood. The underlying cause was soon revealed: Barth syndrome. The disease impairs cells' mitochondria, which are kind of like tiny batteries that generate energy for cells to function correctly. The chromosomal disorder almost exclusively affects boys. Roughly 85% of early deaths occur before age 5. Those who survive longer are usually given heart medications and may need a heart transplant. Kids with Barth syndrome often rely on drugs like beta blockers and ACE inhibitors to keep their hearts functioning as well as possible. Gilbert was fortunate, at least initially. He found a lifeline through access to the treatment from Stealth. Elamipretide, a daily injection, works by helping to repair the damaged mitochondria. In clinical trials, like the one the Drydens participated in, patients showed a 45% improvement in muscle strength and a 40% improvement in heart function, according to the drugmaker. Most participants have safely remained on the drug for over eight years. In October 2024, an advisory committee to the FDA voted 10-6 in support of the therapy, paving the way for the agency to clear the first drug to treat Barth syndrome. The FDA isn't required to follow the advisory committee's guidance, but it almost always does. A spokesman for the Department of Health and Human Services, which oversees the FDA, wrote in an email that the 'FDA did carefully consider the advice of the advisory committee members, including their rationale for their vote. While there is often a high rate of agreement between FDA and advisory committee recommendations,' the spokesman said, 'there is not always concordance.' 'Compelling medical need' for approval After the advisory committee's recommendation, the FDA's rejection was unexpected. 'It is a small sample size,' said a former FDA official who was involved in the drug approval process. The person asked not to be identified in order to speak freely. But the former official was quick to point out that given the advisory committee recommendation for approval, the 'incredibly compelling medical need' of those living with Barth syndrome and the small sample of individuals who seemed to have benefited from the treatment, it certainly appeared that elamipretide was going to make it across the finish line. A lack of continuity in leadership, however, may have added to the already difficult challenge of guiding the treatment through the final hurdles, the former official said. The FDA has seen many top officials leave the agency in recent months. 'Those who have taken over are not as familiar, or perhaps it'd be more appropriate to say they're inexperienced with how one does drug approvals, how one drives things forward, and they're also somewhat fearful of the current environment,' the former official said. 'And I think that's led to an adverse outcome for some of these rare disease products.' The HHS spokesperson didn't immediately respond to a request Monday for comment about the agency's rejection of the drug or leadership issues. A Wall Street Journal Op-Ed recently offered a scathing evaluation of what's happening at the FDA, questioning whether the agency and Commissioner Marty Makary's stated goal of accelerating lifesaving drugs is matching the reality of their actions. The Journal said that there were averages of 52 annual drug approvals under the first Trump administration and 48 under President Joe Biden, but 'there have been only 22 in the first seven months of this year,' projecting to just 38 for the year. Elamipretide was cited in the Journal piece as a casualty of the current environment. The former FDA official pointed out that the treatment hit stumbling blocks under the previous administration, as well, but it was headed in the right direction. 'Now it feels like a hot potato that's been just thrown around,' the former official said. 'And this is just not right. It's just not right.' Families left with few alternatives The Drydens say the FDA decision pulled the rug out from underneath them — and many other families. Dr. Kathryn Chatfield, Gilbert's doctor and a specialist in pediatric cardiology and genetics at Children's Hospital Colorado, said the FDA's inaction leaves families with few alternatives. 'We just don't know what's going to happen,' Chatfield said. 'We're going to have to watch them really closely because they're at risk for recurrence of heart failure and rehospitalization and potentially decompensation to the point where they have to live in the hospital until they could get a heart transplant.' A transplant addresses the heart problem but doesn't alleviate ongoing muscular and skeletal problems. 'I can't be OK with sacrificing my child's life for a bureaucratic process,' Madison Dryden said. The latest hurdle to approval has Barth syndrome families and advocates alike, including some members of Congress, looking for more information and answers. 'Time is of the essence here, and we need to get these drugs to these patients as soon as possible,' said Rep. Buddy Carter, R-Ga., a member of the Energy and Commerce subcommittee on health. Carter spoke to NBC News days before the FDA requested a resubmission in early August and said he'd sent a letter to the agency asking for 'clarity' on elamipretide. 'There aren't that many options out there,' he said. 'In fact, for Barth Syndrome, this elamipretide is really the only drug that we know of that works.' Carter said that there are six families in Georgia alone he's been in contact with who have a loved one with the rare disease. He's hopeful that an 'accelerated pathway' request might prove a viable option for the families and for the company to continue its research. After the recent FDA decision, Carter told NBC News in a statement that he's 'disappointed' with the recommendation 'now that all issues appear to be resolved.' Carter said he's continuing to put pressure on the FDA and that 'patients will suffer with further delays.' He also acknowledged that the economics of a private company, like Stealth, attempting to continue developing a drug for such a small population of patients would be exceedingly difficult without FDA backing. He said he feels deeply for the families in the middle of a terrifying ordeal. 'I'd be calling everybody I could (too), making sure that my child or my grandchild had this medication,' he said in an interview. Madison Dryden and her husband are left with what they call a 'giant unknown' in the absence of approval, struggling for an explanation for their 7- and 3-year-old daughters as families are in a race against time to keep loved ones alive. 'They know that somebody is not giving permission for Gilbert to have his medicine, and that they keep saying no, and they're our kids — like they can't lose … we can't have them lose their baby brother to this,' she said.
Yahoo
8 hours ago
- Yahoo
Veradigm Appoints Don Trigg as Chief Executive Officer
Former apree health CEO, Cerner President will Lead Next Phase of Company Growth CHICAGO, August 18, 2025--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that its Board of Directors has appointed Don Trigg, an industry leader with over two decades of healthcare technology experience, as the Company's new Chief Executive Officer and member of the Board, effective as of September 2, 2025. Trigg was most recently CEO of apree health. The company, acquired by Elevance Health in 2024, develops and delivers innovative advanced primary care solutions, deploys digital engagement and advocacy services to help patients access care, and supports independent primary care practices with its data and technology solutions. Under Trigg's leadership, apree's innovative whole health model earned strong patient satisfaction, drove top-quartile performance on key healthcare effectiveness measures and consistently delivered meaningful reductions in total cost of care. The apree experience reinforced Trigg's conviction regarding the importance of high-quality provider practices and the critical role data and technology can play in supporting them. Prior to apree, Trigg worked between 2003 to 2010 and again from 2013 to 2021 at Cerner Corporation, a $5 billion revenue healthcare IT and services leader, most recently serving as President. As President, Trigg held full P&L and operational responsibilities for the breadth of Cerner's business groups, including Cerner's foundational electronic medical record (EMR), revenue cycle and Strategic Growth businesses, including its life science and data business. Leading up to his role as President, Trigg held senior roles of increasing revenue and strategic responsibility within Cerner, including overseeing global operations in the United Kingdom and Ireland, and creating the company's government practice. During his tenure at Cerner, he successfully modernized multiple legacy technical platforms, helped scale global development teams, and meaningfully moved Cerner beyond the hospital EMR into adjacent and new markets. "Every Veradigm client is looking to improve clinical, operational, and financial performance," said Trigg. "Veradigm's solutions strengthen clinical quality, reduce administrative burdens, and lower healthcare costs. It is a strong foundation for the next phase of growth for Veradigm, and I am excited to have the opportunity to help advance it." "Don's career accomplishments have been driven by strategic vision and execution excellence. His history of demonstrated success in related markets makes Don a compelling leader ideally positioned to deliver growth, innovation, and industry leadership to Veradigm clients and shareholders," said Lou Silverman, Chairman of the Board. "There is immense opportunity embedded in Veradigm. Hard work, dedication, quality assets, and team talent will transform opportunity into accomplishment." About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved. Disclaimer and Forward-Looking Statement Information This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, the Company's strategic initiatives under its new leadership. These forward-looking statements are based on the current beliefs and expectations of the Company's management with respect to future events, only speak as of the date that they are made, and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as "future," "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "will," "would," "could," "continue," "can," "may," "look forward," "aims," "hopes," and "seeks" and similar terms, although not all forward-looking statements contain such words or expressions. Actual results could differ significantly from those set forth in the forward-looking statements. Important factors that may cause actual results to differ materially from those in the forward-looking statements include, among others: risks relating to the Company's common stock not trading on a national securities exchange and deregistration from Section 12(b) of the Securities Exchange Act of 1934, as amended; a further material delay in the Company's financial reporting or ability to hold an annual meeting of stockholders; an inability of the Company to timely prepare its delinquent financial statements; unanticipated factors or factors that the Company currently believes will not cause further delay; the Company's remediation efforts and preparation of financial statements or other factors that could cause additional delay or adjustments; the possibility that ongoing remediation work or the audit of the Company's financial statements for the fiscal year ended December 31, 2023 or the fiscal year ended December 31, 2024 may identify additional errors and material weaknesses or other deficiencies in the Company's accounting practices; the likelihood that the control deficiencies identified or that may be identified in the future will result in additional material weaknesses in the Company's internal control over financial reporting; risks relating to the Company's voluntary disclosure to the SEC of certain information relating to the investigation by the Audit Committee of the Company's Board of Directors, the SEC's investigation, and the additional information the Company has continued to provide to the SEC based on discussions with the SEC; risks relating to the putative securities class action lawsuit filed against the Company, the putative stockholder derivative action filed against the Company, commercial litigation relating to the Company's representations regarding its financial statements and any other future litigation or investigation relating to the Company's internal control failures, the completed investigation, and reviews or related matters; changes in the financial condition of the markets that the Company serves; the Company's ability to hire qualified individuals to serve in senior leadership roles on a permanent basis, including a chief financial officer; risks associated with the Company's incurrence of additional debt and the terms and conditions of the Company's $100 million senior secured term loan credit facility entered into in June 2025; and other factors contained in the "Risk Factors" section and elsewhere in the Company's filings with the SEC from time to time, including, but not limited to, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The Company does not undertake to update any forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes over time, except as required by law. View source version on Contacts Veradigm Contacts: Investors: Jenny Media: Rick Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
